Valneva's Core Vaccine Business Provides Stability Amid Pipeline Transition

Valneva reports €174.7M in 2025 revenue, bolstered by travel vaccines and a U.S. DoD contract, as it navigates Chikungunya setback and awaits key Lyme & Shigella trial data.

While Valneva's voluntary withdrawal of its Chikungunya vaccine from the U.S. market in January dealt a significant blow, the company's latest annual figures for 2025 reveal a resilient foundation. The firm's established travel vaccine division is providing crucial financial stability as investors await key clinical trial results. This core business is funding the operational endurance needed for the biotech's next phase.

Financial Performance and Government Backing

For the full 2025 financial year, Valneva reported total revenues of €174.7 million. Its net loss widened to €115.2 million, a result the company attributes primarily to the absence of one-time effects recorded in the prior year. A standout performer was the Japanese encephalitis vaccine IXIARO, which continues to be a robust revenue driver. This strength was further solidified in January 2025 by a contract with the U.S. Department of Defense valued at a minimum of $32.8 million. Management anticipates a follow-on order from the U.S. government in 2026.

With a cash position of €109.7 million at the end of 2025, Valneva maintains operational flexibility. For the current year, the board is targeting product sales between €145 million and €160 million. The expected decline compared to 2025 is largely due to a planned reduction in third-party product sales.

Navigating the Chikungunya Setback

The situation surrounding the Chikungunya vaccine IXCHIQ is more challenging. Following a temporary suspension by the U.S. FDA in the summer of 2025, Valneva made the decision to formally withdraw its U.S. marketing applications early this year. The vaccine remains commercially available outside the United States, where it generated €8.4 million in revenue during 2025.

Market sentiment has turned cautious in light of these developments. The stock recently recorded a single-day decline of 3.27 percent, with its last quoted price at €4.37.

Upcoming Catalysts in the Clinical Pipeline

Attention is now pivoting to Valneva's clinical development pipeline, with important milestones expected soon. By mid-2026, the company anticipates Phase 2 data for its in-licensed Shigella vaccine candidate, S4V2. Furthermore, positive results for the Lyme disease vaccine candidate VLA15 could trigger partner Pfizer to submit regulatory filings before year-end. Company leadership believes that a successful commercialization of VLA15 would chart a clear course toward sustained profitability for Valneva.